Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Alecta in connection with investment in Stena Renewable
Mandate

Vinge advises Alecta in connection with investment in Stena Renewable

April 01, 2021 M&A Environmental Law

Vinge has advised Alecta in connection with an investment of SEK 1.6 billion in Stena Renewable AB, of which SEK 600 million will be invested over a 5-year period.

The investment is Alecta’s first direct investment in green energy and, following completion of the transaction, Alecta will own 20 per cent of the shares in Stena Renewable. The other shareholders of the company are Stena Adactum, AMF and Norway’s largest pension company, KLP.

Stena Renewable develops, constructs and operates onshore wind farms. The company currently has 115 wind turbines located on eight wind parks in Sweden.

Vinge’s team mainly consisted of Filip Öhrner, Peter Sundgren, Manne Bergström, Carl Fredrik Wachtmeister (M&A) and Johan Cederblad (Environmental law/Real Estate).

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025